In addition to the previous PD-1/PD-L1 inhibitors, nivolumab has been investigated in treating advanced MCC, achieving an ORR of 68% (CheckMate 358 phase I/II trial, NCT02488759). The gene discussed is CD274; the disease is Merkel cell skin cancer.